{
    "code": "02022449",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022449",
    "time": "2019-03-22 03:04:39",
    "許可證字號": "衛署藥輸字第022449號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "113\/04\/08",
    "發證日期": "88\/04\/08",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202244909",
    "中文品名": "癌康定注射劑",
    "英文品名": "HYCAMTIN 4MG INJECTION",
    "適應症": "卵巢癌及小細胞肺癌之第二線化學治療（第一線化療應包括白金化合物） Hycamtin與cisplatin併用適用於治療經組織學檢查確定患有第IV-B期復發性或持續性子宮頸癌，且不適合以外科手術及（或）放射療法進行治療的患者",
    "劑型": "243凍晶注射劑",
    "包裝": "小瓶 盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "TOPOTECANHYDROCHLORIDE"
    ],
    "限制項目": "02輸　入",
    "申請商名稱": "0924601100  台灣諾華股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F250339000  GLAXO SMITHKLINE MANUFACTURING S.P.A.",
        "製造廠廠址": "STRADA PROVINCIALE ASOLANA 90, 43056 SAN POLO DI TORRILE PARMA, ITALY",
        "製造廠公司地址": ""
    },
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000310",
            "成分名稱": "TOPOTECAN HYDROCHLORIDE",
            "含量描述": "",
            "含量": "4.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "癌康定注射液-TWI-020119-108-02-23.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022449&Seq=023&Type=9"
        },
        {
            "title": "Hycamtin M131-600-02-104-09-30(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022449&Seq=002&Type=8"
        }
    ]
}